

# Drug Utilization Review Board

(DUR Board)

Meeting – September 10, 2008 @ 6:00 p.m.

Oklahoma Health Care Authority

4545 N. Lincoln Suite 124

Oklahoma City, Oklahoma 73105

Oklahoma Health Care Authority Board Room

---

## **AGENDA**

Discussion and Action on the Following Items:

Items to be presented by Dr. McNeill, Chairman:

1. **Call To Order**
  - A. Roll Call – Dr. Graham

Items to be presented by Dr. McNeill, Chairman:

2. **Public Comment Forum**
  - A. Acknowledgment of Speakers and Agenda Item

Items to be presented by Dr. McNeill, Chairman:

3. **Action Item – Approval of DUR Board Meeting Minutes – See Appendix A.**
  - A. August 13, 2008 DUR Minutes – Vote
  - B. August 14, 2008 DUR Recommendations Memorandum

Items to be presented by Dr. Keast, Dr. McNeill, Chairman:

4. **Update on DUR/MCAU Program – See Appendix B.**
  - A. Retrospective Drug Utilization Review Responses for February 2008
  - B. Medication Coverage Activity Audit for August 2008
  - C. Help Desk Activity Audit for August 2008

Items to be presented by Dr. Keast, Dr. McNeill, Chairman:

5. **Vote to Prior Authorize Erythropoiesis Stimulating Agents – See Appendix C.**
  - A. COP Recommendations

Items to be presented by Dr. Moore, Dr. McNeill, Chairman

6. **Vote to Prior Authorize Protonix<sup>®</sup> Suspension – See Appendix D.**
  - A. Current PA Criteria
  - B. COP Recommendations

Items to be presented by Dr. Browning, Dr. McNeill, Chairman

7. **Vote to Prior Authorize Patanase<sup>®</sup> – See Appendix E.**
  - A. Product Summary
  - B. COP Recommendations

Guest Speaker

8. **Hemophilia Presentation by Sarah M. Hawk, P.A.-C., Oklahoma Center for Bleeding and Clotting Disorders – See Appendix F.**
  - A. Utilization Review

Items to be presented by Dr. Le, Dr. McNeill, Chairman

9. **60 Day Notice to Prior Authorize Rescue HFA Products – See Appendix G.**
  - A. Product Summary
  - B. Utilization Review
  - C. COP Recommendations

Items to be presented by Dr. Graham, Dr. McNeill, Chairman

10. **FDA and DEA Updates – See Appendix H.**
  
11. **Future Business**
  - A. Antidepressants
  - B. Oral Antifungal Utilization Review
  - C. Glaucoma Intervention Report
  - D. Annual Reviews
  - E. New Product Reviews
  
12. **Adjournment**